PRECISION BIOSCIENCES INC (DTIL) Stock News

USA - NASDAQ:DTIL - US74019P2074 - Common Stock

6.9 USD

+0.26 (+3.92%)

Last: 10/17/2025, 8:07:18 PM

6.9 USD

0 (0%)

After Hours: 10/17/2025, 8:07:18 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

DTIL Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: Precision BioSciences, Inc.

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025

11 days ago - By: Precision BioSciences, Inc.

Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases

13 days ago - By: Precision BioSciences, Inc.

Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial

2 months ago - By: The Motley Fool

DTIL Revenue Drops 99%

2 months ago - By: Benzinga - Mentions: GSAT PGY ADV REAL ...

Earnings Scheduled For August 7, 2025

5 months ago - By: Benzinga

Uncovering Potential: Precision BioSciences's Earnings Preview

20 days ago - By: Precision BioSciences, Inc.

Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society

a month ago - By: Precision BioSciences, Inc.

Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium

a month ago - By: Precision BioSciences, Inc.

Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status

2 months ago - By: Zacks Investment Research - Mentions: FEMY

Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates

2 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update

2 months ago - By: Zacks Investment Research - Mentions: IMNM

Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates

2 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B

3 months ago - By: Zacks Investment Research - Mentions: QGEN

Qiagen (QGEN) Matches Q2 Earnings Estimates

3 months ago - By: Precision BioSciences, Inc.

Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025

3 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

3 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic

4 months ago - By: Stocktwits

Precision Bio's DMD Therapy Gets Rare Pediatric Status, But Stock Slides; Retail Crowd Sees ‘Good Risk-Reward’

4 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

5 months ago - By: ACCESS Newswire - Mentions: ULY HTCR DGXX LWLG ...

Sidoti Events, LLC's Virtual May Micro-Cap Conference

5 months ago - By: Zacks Investment Research - Mentions: FBIO

Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates

5 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

5 months ago - By: Zacks Investment Research - Mentions: ARMP

Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates

5 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

5 months ago - By: Zacks Investment Research - Mentions: AKYA

Akoya Biosciences (AKYA) Reports Q1 Loss, Misses Revenue Estimates

5 months ago - By: Precision BioSciences, Inc.

Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025

6 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)

6 months ago - By: Zacks Investment Research - Mentions: DVAX

Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates

6 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

6 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

7 months ago - By: Precision BioSciences, Inc.

Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

7 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update

7 months ago - By: Precision BioSciences, Inc.

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

7 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025